Wave rides new Phase 2 DMD data as it sets sights on accelerated approval

Max Bayer

Pharma Reporter

Lei Lei Wu

News Reporter

Wave Life Sciences said new Phase 2 biomarker data for its exon-skipping therapy are promising for certain patients with Duchenne muscular dystrophy, and it plans …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Wave rides new Phase 2 DMD data as it sets sights on accelerated approval

Max Bayer

Pharma Reporter

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Jazz wins approval for bispecific in biliary tract cancer

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?

Wave rides new Phase 2 DMD da­ta as it sets sights on ac­cel­er­at­ed ap­proval

Pharma Reporter

News Reporter

Sign up to read this article for free.

Wave rides new Phase 2 DMD data as it sets sights on accelerated approval